A review of randomized, controlled trials in the literature investigated the efficacy of a 12-week schedule of zoledronic acid for bone metastasis vs a 4-week schedule.
A meta-analysis sought to determine if survival is improved with dual targeting of the MAPK pathway with BRAF and MEK inhibitors vs BRAF inhibition alone in patients with advanced melanoma.
A retrospective study sought to determine the efficacy of dexamethasone in preventing cutaneous reactions associated with pemetrexed-based regimens for pulmonary adenocarcinoma.
A review of cancer-related PTSD, its causes, and steps oncology nurses can take to ease the burden of this adverse effect on patients and their caregivers.
An expanded treatment protocol study sought to validate the safety and efficacy of ruxolitinib, a JAK kinase inhibitor approved by the FDA for the treatment of polycythemia vera in patients who are intolerant of, or resistant to, hydroxyurea.
A retrospective study assessed the severity of gastrointestinal toxicity in patients treated with rituximab and evaluated various management approaches.
Two randomized phase 3 trials investigating the safety and efficacy of adding pembrolizumab to standard-of-care therapies for multiple myeloma were halted due to poor outcomes in their respective intervention arms.
Key factors that influence choice of TKI for frontline treatment of chronic-phase CML are reviewed, as well as the role for pharmacists in the multidisciplinary oncology care team.
Retrospective population-based cohort study is used to validate a new risk assessment tool to identify patients receiving immunomodulatory drugs for multiple myeloma who may be at high risk of VTE.
Laser, other light tx recommended for patients treated with HSCT; head and neck RT with, without chemo.